The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10116 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin combination therapy (ACT)

NOT Open Access | Decreasing pfmdr1 Copy Number Suggests that Plasmodium falciparum in Western Cambodia Is Regaining In Vitro Susceptibility to Mefloquine

April 14, 2015 - 17:36 -- NOT Open Access
Author(s): 
Pharath Lim, Dalin Dek, Vorleak Try, Sokunthea Sreng, Seila Suon, and Rick M. Fairhurst
Reference: 
Antimicrob. Agents Chemother. May 2015 vol. 59 no. 5 2934-2937

Dihydroartemisinin-piperaquine is the current frontline artemisinin combination therapy (ACT) for Plasmodium falciparum malaria in Cambodia but is now failing in several western provinces.

Country: 

Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy

March 31, 2015 - 17:31 -- Open Access
Author(s): 
Nahla B Gadalla, Gloria Tavera, Jianbing Mu, Edward R Kabyemela, Michael Fried, Patrick E Duffy, Juliana M Sá, Thomas E Wellems
Reference: 
Malaria Journal 2015, 14:129 (25 March 2015)

The pfcrt-CVIET chloroquine resistance haplotype dominated in the collection of P. falciparum samples from Muheza.

Country: 

Patient adherence to prescribed artemisinin-based combination therapy in Garissa County, Kenya, after three years of health care in a conflict setting

March 25, 2015 - 15:42 -- Open Access
Tags: 
Author(s): 
Georgia R Gore-Langton, Nfornuh Alenwi, Richard Allan, et al.
Reference: 
Malaria Journal 2015, 14:125 (24 March 2015)

Sustaining the ACT adherence rates at the 2010 levels, through 2.5 years of insecurity in the study area is an achievement and suggests that if security can be improved barriers to improving health service quality and patient adherence to AL would be removed.

Country: 

Are Tanzanian patients attending public facilities or private retailers more likely to adhere to artemisinin-based combination therapy?

March 2, 2015 - 18:43 -- Open Access
Author(s): 
Katia Bruxvoort, Admirabilis Kalolella, Matthew Cairns, Charles Festo, Mitya Kenani, Peter Lyaruu, S Kachur, David Schellenberg, Catherine Goodman
Reference: 
Malaria Journal 2015, 14:87 (19 February 2015)

When controlling for patient characteristics, there was some evidence that the adjusted odds of adherence for ADDO patients was lower than that for public health facility patients.

Dried whole-plant Artemisia annua slows evolution of malaria drug resistance and overcomes resistance to artemisinin

January 28, 2015 - 16:26 -- Open Access
Author(s): 
Mostafa A. Elfawal, Melissa J. Towler, Nicholas G. Reich, Pamela J. Weathers, Stephen M. Rich
Reference: 
PNAS January 20, 2015 vol. 112 no. 3 821-826

Pharmaceutical monotherapies against human malaria have proven effective, although ephemeral, owing to the inevitable evolution of resistant parasites.

Dried-leaf Artemisia annua: A practical malaria therapeutic for developing countries?

December 15, 2014 - 16:03 -- Open Access
Tags: 
Author(s): 
Pamela J Weathers, Melissa Towler, Ahmed Hassanali, Pierre Lutgen and Patrick Ogwang Engeu
Reference: 
World J Pharmacol. 2014 December 9; 3(4): 39-55

Artemisinin from the plant Artemisia annua (A. annua) L., and used as artemisinin combination therapy (ACT), is the current best therapeutic for treating malaria, a disease that hits children and adults especially in developing countries.

Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review

December 11, 2014 - 05:08 -- Open Access
Author(s): 
Benjamin J Visser, Rosanne W Wieten, Daniëlle Kroon, Ingeborg M Nagel, Sabine Bélard, Michèle van Vugt, Martin P Grobusch
Reference: 
Malaria Journal 2014, 13:463 (26 November 2014)

ACT is at least equivalent to chloroquine in effectively treating non-falciparum malaria.

Artemisinin Combination Therapy: A Good Antimalarial, but Is the Dose Right?

December 10, 2013 - 06:52 -- Open Access
Author(s): 
Paul Garner
Reference: 
PLoS Med 10(12): e1001565

Artemisinin combination therapy (ACT) has revolutionised malaria treatment. ACTs combine an artemisinin derivative (a relatively new group of very effective drugs  with another longer-lasting drug from another class to try to reduce the risk of further resistance developing. ACTs cure over 90% of people; they also act against malaria gametocytes, so potentially reduce transmission.

Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 cases

November 13, 2013 - 08:49 -- Open Access
Author(s): 
Cordel H, Cailhol J, Matheron S, Bloch M, Godineau N, Consigny P, Gros H, Campa P, Bourée P, Fain O, Ralaimazava P, Bouchaud O
Reference: 
Malaria Journal 2013, 12 :399 (7 November 2013)
MalariaWorld

This study seems to be the largest in terms of number of imported uncomplicated malaria cases treated by AP.

Pages

Subscribe to RSS - artemisinin combination therapy (ACT)